Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 840
External Links
Identifiers
- ORCID
- 0000-0003-3504-2633
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.